📗 Cite This Artifact
mechanism-categories-pathways
Mechanism Categories & Pathways
Overview
This page organizes the diverse mechanisms of neurodegeneration into coherent categories and pathway frameworks. Understanding mechanism categories helps identify shared biology across diseases and prioritize therapeutic targets. [@mechanistic2023]
Neurodegenerative mechanisms can be grouped into several major categories: protein aggregation, cellular quality control, inflammation, metabolism, and synaptic dysfunction. [@protein2022]
--- [@neuroinflammation2023]
Major Mechanism Categories
Protein Aggregation
Amyloid Pathways [@mitochondrial2022]
- [Amyloid-beta](/proteins/amyloid-beta) production ([APP](/entities/app-protein) processing)
- Amyloid-beta aggregation
- Amyloid plaque formation
- Cerebral amyloid angiopathy
- Tau phosphorylation
- Tau aggregation
- Neurofibrillary tangle formation
- Tau spread (prion-like)
- [Alpha-synuclein](/proteins/alpha-synuclein) expression
- Post-translational modifications
- Oligomerization
- Lewy body formation
- TDP-43 mislocalization
- TDP-43 aggregation
- RNA splicing disruption
Cellular Quality Control
Protein Homeostasis
...
Mechanism Categories & Pathways
Overview
This page organizes the diverse mechanisms of neurodegeneration into coherent categories and pathway frameworks. Understanding mechanism categories helps identify shared biology across diseases and prioritize therapeutic targets. [@mechanistic2023]
Neurodegenerative mechanisms can be grouped into several major categories: protein aggregation, cellular quality control, inflammation, metabolism, and synaptic dysfunction. [@protein2022]
--- [@neuroinflammation2023]
Major Mechanism Categories
Protein Aggregation
Amyloid Pathways [@mitochondrial2022]
- [Amyloid-beta](/proteins/amyloid-beta) production ([APP](/entities/app-protein) processing)
- Amyloid-beta aggregation
- Amyloid plaque formation
- Cerebral amyloid angiopathy
- Tau phosphorylation
- Tau aggregation
- Neurofibrillary tangle formation
- Tau spread (prion-like)
- [Alpha-synuclein](/proteins/alpha-synuclein) expression
- Post-translational modifications
- Oligomerization
- Lewy body formation
- TDP-43 mislocalization
- TDP-43 aggregation
- RNA splicing disruption
Cellular Quality Control
Protein Homeostasis
| Mechanism | Key Players | Therapeutic Approach |
|-----------|-------------|-------------------|
| [Autophagy](/entities/autophagy) | [mTOR](/mechanisms/mtor-signaling-pathway), ULK1, Atg proteins | Activators |
| Proteasome | Ubiquitin, 26S complex | Enhancers |
| ER-associated degradation | Sel1L, HRD1 | Modulators |
| Molecular chaperones | Hsp70, Hsp90 | Inducers |
Mitochondrial Quality Control
| Mechanism | Key Players | Therapeutic Approach |
|-----------|-------------|-------------------|
| Mitophagy | PINK1, PARKIN | Activators |
| Mitochondrial dynamics | [Drp1](/proteins/drp1-protein), Mfn1/2, OPA1 | Modulators |
| Mitochondrial biogenesis | PGC-1alpha | Activators |
| Mitochondrial transfer | Tunneling nanotubes | Enhancement |
Neuroinflammation
Microglial Activation
Disease-Associated [Microglia](/cell-types/microglia-neuroinflammation) (DAM)
- [TREM2](/proteins/trem2)-dependent activation
- [APOE](/proteins/apoe)-mediated pathways
- [Complement system](/entities/complement-system) involvement
- Phagocytosis regulation
- [NF-κB](/entities/nf-kb) signaling
- [NLRP3 inflammasome](/entities/nlrp3-inflammasome)
- Cytokine production
- [ROS](/entities/reactive-oxygen-species) generation
Astrocyte Reactivity
A1 (Neurotoxic) [Astrocytes](/entities/astrocytes)
- Triggered by microglia
- Loss of supportive functions
- Neurotoxic factor secretion
- Growth factor secretion
- Synapse support
- Tissue repair
Cellular Metabolism
Energy Metabolism
| Pathway | Dysfunction | Therapeutic |
|---------|------------|-------------|
| Glycolysis | Reduced | Metabolic enhancers |
| TCA cycle | Impaired | Co-factor supplementation |
| OXPHOS | Defective | Mitochondrial modulators |
| Fatty acid oxidation | Reduced | Metabolic shift |
Lipid Metabolism
- APOE-mediated lipid transport
- Myelin maintenance
- Membrane phospholipids
- Cholesterol homeostasis
Synaptic Dysfunction
Synaptic Loss Mechanisms
- Excitotoxicity
- Synaptic protein aggregation
- Vesicle trafficking disruption
- Postsynaptic density alterations
Network Dysfunction
- Circuit hypersynchrony
- Oscillation abnormalities
- Functional connectivity loss
- Network hub vulnerability
Cell Death Pathways
Necrosis
- Energy depletion
- Membrane rupture
- Inflammation
Apoptosis
- Intrinsic (mitochondrial) pathway
- Extrinsic (death receptor) pathway
- Caspase activation
- DNA fragmentation
Autophagy-Dependent Cell Death
- Excessive autophagy
- Lysosomal membrane permeabilization
- Autophagic stress
Cross-Disease Mechanisms
Many mechanisms are shared across neurodegenerative diseases:
| Mechanism | AD | PD | ALS | FTD |
|-----------|-----|-----|------|------|
| Protein aggregation | Yes | Yes | Yes | Yes |
| Mitochondrial dysfunction | Yes | Yes | Yes | Yes |
| Neuroinflammation | Yes | Yes | Yes | Yes |
| Synaptic loss | Yes | Yes | Yes | Yes |
| Oxidative stress | Yes | Yes | Yes | Yes |
Epigenetic Mechanisms
DNA Modifications
| Modification | Function | Role in Neurodegeneration |
|--------------|----------|--------------------------|
| DNA methylation | Gene silencing | Altered in AD, PD |
| 5-hmC (hydroxymethylation) | Active demethylation | Reduced in AD |
| Histone acetylation | Gene activation | Dysregulated in several disorders |
Non-Coding RNAs
| Type | Example | Disease Association |
|------|---------|---------------------|
| microRNA | miR-29, miR-124 | AD, PD |
| siRNA | Various | Target validation ongoing |
| lncRNA | MALAT1, NEAT1 | Neuroinflammation |
Cellular Stress Response
Heat Shock Response
- Hsp90 inhibitors: Target misfolded protein aggregates
- Hsp70 inducers: Promote protein folding
- Hsp40 family: Co-chaperones for aggregate clearance
Unfolded Protein Response (UPR)
| Branch | Activation | Therapeutic Target |
|--------|------------|-------------------|
| IRE1 | Accumulation of misfolded proteins | XBP1 splicing modulators |
| PERK | eIF2α phosphorylation | Integrated stress response |
| ATF6 | ER stress | ATF6 activators |
Therapeutic Implications
Understanding mechanism categories enables:
Emerging Mechanism Categories
Glial-Neuronal Interactions
| Interaction | Mechanism | Therapeutic Potential |
|-------------|-----------|----------------------|
| Microglia-neuron | TREM2 signaling | Agonists in development |
| Astrocyte-neuron | Metabolic coupling | Neuroprotective factors |
| Oligodendrocyte-neuron | Myelin maintenance | Remyelination strategies |
Network-Level Mechanisms
| Mechanism | Description | Biomarkers |
|-----------|-------------|------------|
| Network hypersynchrony | Excessive neuronal synchronization | EEG, MEG |
| Oscillation disruption | Abnormal brain rhythms | Sleep EEG |
| Functional connectivity loss | Decreased inter-regional connectivity | fMRI |
Neurovascular Dysfunction
| Component | Dysfunction | Disease Association |
|-----------|------------|---------------------|
| Blood-brain barrier | Increased permeability | AD, MS |
| Cerebral blood flow | Reduced perfusion | Vascular cognitive impairment |
| Neurovascular unit | Coupling breakdown | AD, PD |
Proteostatic Network Collapse
| System | Role | Therapeutic Target |
|--------|------|-------------------|
| Chaperone networks | Protein folding | Hsp90/70 modulators |
| Autophagy-lysosomal | Protein clearance | mTOR inhibitors |
| Ubiquitin-proteasome | Targeted degradation | UPS enhancers |
| ER-associated degradation | Misfolded protein clearance | SEL1L modulators |
Cross-Disease Therapeutic Strategies
Shared Target Approaches
Combination Therapy Rationale
| Target Combination | Rationale | Example |
|-------------------|-----------|---------|
| Anti-aggregation + Anti-inflammatory | Multiple pathway inhibition | AD trials |
| Mitochondrial + Metabolic | Energy deficit correction | PD trials |
| Synaptic + Neurotrophic | Restore neuronal function | Multiple disorders |
Systems-Level Mechanisms
Circadian Rhythm Dysregulation
The circadian system plays a crucial role in brain health, and its disruption contributes to neurodegeneration:
| Component | Role in Neurodegeneration | Therapeutic Approach |
|-----------|--------------------------|---------------------|
| Suprachiasmatic nucleus | Master clock dysfunction | Light therapy, chronobiotics |
| BMAL1/CLOCK | Circadian gene dysregulation | SIRT1 modulators |
| Melatonin signaling | Antioxidant, sleep regulation | Melatonin agonists |
| Sleep-wake cycles | Protein clearance enhancement | Sleep optimization |
Autonomic Nervous System Involvement
| Component | Dysfunction | Disease Association |
|-----------|------------|---------------------|
| Sympathetic overactivity | α-synuclein spread | PD, MSA |
| Parasympathetic dysfunction | Gastrointestinal symptoms | PD prodrome |
| Cardiovascular dysregulation | Orthostatic hypotension | Multiple system atrophy |
| Enteric nervous system | Lewy body formation | PD |
Disease-Specific Mechanisms
Alzheimer's Disease
| Mechanism Category | Key Pathways | Therapeutic Targets |
|-------------------|-------------|-------------------|
| Amyloidogenic | APP processing, Aβ production | BACE inhibitors, antibodies |
| Tauopathy | Hyperphosphorylation, propagation | Anti-tau antibodies, kinase inhibitors |
| Neuroinflammation | Microglial activation, complement | TREM2 agonists, NLRP3 inhibitors |
| Metabolic | Insulin resistance, glucose dysregulation | GLP-1 analogs, metabolic modulators |
Parkinson's Disease
| Mechanism Category | Key Pathways | Therapeutic Targets |
|-------------------|-------------|-------------------|
| α-Synucleinopathy | Aggregation, spreading | Immunotherapies, aggregation inhibitors |
| Mitochondrial dysfunction | Complex I deficiency, PINK1/Parkin | Mitochondrial antioxidants |
| Neuroinflammation | Microglial activation, TNF-α | Minocycline, microglial inhibitors |
| Neurotransmitter loss | Dopaminergic cell death | GDNF, cell replacement |
Amyotrophic Lateral Sclerosis
| Mechanism Category | Key Pathways | Therapeutic Targets |
|-------------------|-------------|-------------------|
| Protein aggregation | TDP-43, SOD1 | ASOs, gene silencing |
| Excitotoxicity | Glutamate, AMPA receptors | Riluzole, perampanel |
| Mitochondrial dysfunction | Energy failure, ROS | Edaravone, metabolic support |
| Neuroinflammation | Microglial activation | Ibudilast, colony-stimulating factors |
Frontotemporal Dementia
| Mechanism Category | Key Pathways | Therapeutic Targets |
|-------------------|-------------|-------------------|
| Tau pathology | MAPT mutations, tau aggregation | Anti-tau therapies |
| TDP-43 pathology | C9orf72, TARDBP mutations | Gene therapy approaches |
| Neuroinflammation | Microglial activation | Immunomodulation |
| Synaptic dysfunction | PSD95, synaptophysin loss | Synaptic protectors |
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Inflammation Mechanisms
Neuroinflammation
Glial activation:
- Microglial activation
- Astrocyte reactivity
- Cytokine release
- Complement system
Inflammasome Activation
NLRP3 pathway:
- Priming step
- Activation step
- Caspase-1 activation
- IL-1β release
Metabolic Mechanisms
Mitochondrial Dysfunction
Key processes:
- Electron transport chain
- ATP production
- ROS generation
- Apoptosis pathways
Oxidative Stress
Sources:
- Mitochondrial ROS
- Metal accumulation
- Enzyme dysfunction
- Inflammation
Synaptic Mechanisms
Synapse Loss
Processes:
- Excitotoxicity
- Synaptic pruning
- Transport defects
- Mitochondrial dysfunction
Neurotransmitter Dysfunction
Systems affected:
- Dopaminergic
- Cholinergic
- Glutamatergic
- GABAergic
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-mechanism-categories-pathways |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-e4648c81a265 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mechanism-categories-pathways'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-mechanism-categories-pathways?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[mechanism-categories-pathways](http://scidex.ai/artifact/wiki-mechanisms-mechanism-categories-pathways)
http://scidex.ai/artifact/wiki-mechanisms-mechanism-categories-pathways